InterMune, Inc. has completed the sale of worldwide ownership of Amphotec / Amphocil (amphotericin B cholesteryl sulfate complex for injection) to Three Rivers Pharmaceuticals, LLC.
Amphotec is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immunocompromised patients. Financial terms of the agreement, which was signed and executed on May 20, 2005, were not disclosed.
The divestiture of Amphotec was part of a previously announced strategy by InterMune and will not affect the Company's 2005 total revenue guidance of $140-160 million, a release from InterMune said.
"Because invasive aspergillosis falls outside of InterMune's two areas of therapeutic focus, hepatology and pulmonology, we decided it was in the best interest of both shareholders and patients to divest this product," stated Dan Welch, InterMune's president and CEO.